Aims and Scope of CNS Neuroscience and Therapeutics
CNS Neuroscience & Therapeutics is a bimonthly medical journal published 1995 by Wiley-Blackwell addressing topics in neurology and central nervous system therapeutic pharmacology. It was established in 1995 as CNS Drug Reviews and obtained its current title in 2008. Less
Key Metrics
CiteScore 

8.9
Eigenfactor 

0.005 - 0.01
Impact Factor 

5 - 10
SJR 

Q1Pharmacology

SNIP 

1.34
Recommended pre-submission checks
Powered by 

Topics Covered on CNS Neuroscience and Therapeutics
CNS Neuroscience and Therapeutics Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | EUR 2150 | GBP 1900 | USD 2530 |
| Publication Time | 14 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1995 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in CNS Neuroscience and Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in CNS Neuroscience and Therapeutics
Development and Validation of Multiple Machine Learning Models Integrating Neutrophil‐Lymphocyte Ratio for Prediction of Hemorrhagic Transformation After Intravenous Thrombolysis in Acute Ischemic Stroke
- 12 Dec 2025
- CNS Neuroscience & Therapeutics
Activation and Long‐Term Maintenance of Adaptive Immunity in the Central Nervous System: A Double‐Edged Sword?
- 12 Dec 2025
- CNS Neuroscience & Therapeutics
Cellular Communication Networks Mediated by Microglia in Ischemic Stroke
- 9 Dec 2025
- CNS Neuroscience & Therapeutics
Perfusion and Structural Impairment in Minor Stroke and Transient Ischemic Attack With Intracranial Atherosclerotic Stenosis: Associations With Cognitive Decline
- 9 Dec 2025
- CNS Neuroscience & Therapeutics
Phase 2 Trial of PD‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma
- 8 Dec 2025
- CNS Neuroscience & Therapeutics
Mfsd2a‐Targeted Therapy for Ischemic Stroke: Mechanisms, Evidence, and Future Prospects
- 8 Dec 2025
- CNS Neuroscience & Therapeutics
Development and Validation of Multiple Machine Learning Models Integrating Neutrophil‐Lymphocyte Ratio for Prediction of Hemorrhagic Transformation After Intravenous Thrombolysis in Acute Ischemic Stroke
- 12 Dec 2025
- CNS Neuroscience & Therapeutics
Activation and Long‐Term Maintenance of Adaptive Immunity in the Central Nervous System: A Double‐Edged Sword?
- 12 Dec 2025
- CNS Neuroscience & Therapeutics
Cellular Communication Networks Mediated by Microglia in Ischemic Stroke
- 9 Dec 2025
- CNS Neuroscience & Therapeutics
Perfusion and Structural Impairment in Minor Stroke and Transient Ischemic Attack With Intracranial Atherosclerotic Stenosis: Associations With Cognitive Decline
- 9 Dec 2025
- CNS Neuroscience & Therapeutics
Phase 2 Trial of PD‐1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma
- 8 Dec 2025
- CNS Neuroscience & Therapeutics
Mfsd2a‐Targeted Therapy for Ischemic Stroke: Mechanisms, Evidence, and Future Prospects
- 8 Dec 2025
- CNS Neuroscience & Therapeutics